
The decision to invest in the company was made to pursue new innovations for the future of life brought about by genome analysis technology!
With the vision of "making genomes more accessible to the public and a world where genomes are taken for granted," Zene is developing healthcare services for corporate customers that achieve high accuracy with genome analysis technology employing the polygenic risk score method (*).
This unique service, which can examine genetic information from saliva collected at home or at work, and visualize the constitution through a report on the results of genome analysis to encourage lifestyle improvement, has gained support from health insurance associations and general businesses that are interested in improving the health of their employees.
Panasonic is committed to creating products, services, and solutions that contribute to the wellbeing of people. We have decided to make this investment in order to acquire multifaceted knowledge and pursue new innovations for the future of life brought about by genome analysis technology.
Panasonic will continue to strengthen its open innovation initiatives based on strong relationships by investing in promising startups in Japan and overseas that have strengths in business areas related to people's lives, such as energy, food infrastructure, spatial infrastructure, and lifestyle.
*Multifactorial analysis that integrates the entire genomic information.
For the full text, please see the press release below.
▼ [PRESS RELEASE] Genome Analysis Service to Zene, Inc.
Investment from Panasonic Kurashi Visionary Fund (March 8, 2024)
https://news.panasonic.com/jp/press/jn240308-4
About Zene
| name of company | Zene Corporation |
| Establishment | February 2020 |
| Location | 4F Otemachi First Square East Tower, 1-5-1 Otemachi, Chiyoda-ku, Tokyo |
| representative | Masahiro Inoue |
| Business Overview | Providing genome analysis services and genome data analysis platform |
| uniform resouce locator | https://www.zene.co.jp/ |









